
News|Videos|October 17, 2023
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series

This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Related to this article

A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.

Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.

A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.

The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.

AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Wen Shen, MD, on recognizing perimenopause as a window for healthy aging
2
IMS: Fezolinetant's improvements in sleep quality, hot flashes as early as week 4
3
FAQ: What does the rename from PCOS to PMOS mean for your patients?
4
Top headlines in women's health from September 2026
5






